Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for KalVista Pharmaceuticals (KALV) over the last 9 years, with Q2 2025 value amounting to -$52.2 million.

  • KalVista Pharmaceuticals' Net Income towards Common Stockholders fell 1698.81% to -$52.2 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$92.7 million, marking a year-over-year decrease of 2578.82%. This contributed to the annual value of -$183.5 million for FY2025, which is 4485.64% down from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$52.2 million for Q2 2025, which was down 1698.81% from -$40.4 million recorded in Q3 2024.
  • KalVista Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at -$29.0 million during Q1 2024, with a 5-year trough of -$52.2 million in Q2 2025.